Tele: 561.316.3330
Breaking Medical Device News

Tuesday, September 21, 2021


HomeEndomagOchsner Health System adopts Magseed® as Standard of Care for Localization of Impalpable Breast Lesions

Ochsner Health System adopts Magseed® as Standard of Care for Localization of Impalpable Breast Lesions

Magseed technology guides surgeons during a breast lumpectomy to simplify treatment and improve patient experience

Endomag, the cancer healthcare company, announced today that Ochsner Health System has adopted Magseed® as the standard of care for breast lesion localization, having identified the system as simpler and more effective than alternative techniques. Magseed was chosen as the preferred alternative to wire localization, based on clinician and patient experience, following trials comparing the benefits of this technology with radioactive seed and radar techniques.

Ochsner Health System chose to move away from traditional wire localization, which is known to be restrictive, lengthy and an uncomfortable procedure for patients. Wire systems must be conducted on the same day as surgery and can result in delays, infection, and a higher risk of cancerous tissue being left behind.

Having explored alternative techniques, including radioactive seed localization (RSL) and radar localization, Ochsner Health System, which provides cancer care to around 15,000 patients per year, found Magseed to provide significant advantages for both surgeon and patient, and has chosen the technology as the Health System’s preferred localization technique for breast lesions.

While RSL provides an alternative to wire techniques and can be conducted several days ahead of surgery, setting up a program can be difficult to coordinate across multiple hospital departments. The procedure also places a heavy burden on clinicians who need to closely track the seeds to ensure radio-labeled material is recovered from the breast specimen.

Radar localization, an alternative non-radioactive technique, uses micro-impulse radar to detect a reflector that is placed at the tumor site up to 30 days ahead of surgery. However, the reflectors are quite large in comparison with Magseed and can be damaged during placement within the lesion. Once inside the breast tissue, the reflector can be difficult to locate from all orientations and a second scanner is required to confirm that it is still working.

“Radar localization was eventually dismissed due to its slower, more cumbersome scanning that made it hard to locate the reflector. By contrast the Sentimag probe was much faster and its immediate feedback made it easier to scan the breast and locate Magseed,” cites Dr Aimee Mackey, Breast Surgeon, Ochsner Health System.

Magseed was identified as the most patient-centered localization technique available, offering the precision of radioseeds without the safety and regulatory concerns associated with radioactive exposure. Magseed cannot be damaged during placement. The clarity of imaging provided by the system enables confident and efficient placement within the breast lesion, and ease of location during surgery. As a result, this technique can be performed rapidly, allowing more patients to benefit from treatment.

Dr Dana Smetherman, Section Head, Breast Imaging, Ochsner Health System, added,“Overall we found that Magseed tackles most of the technical and safety issues associated with wire localization, radioactive seeds, and radar localization. We believe that this is the best technology for our patients. Once they become aware that this technology is available to them, we’re certain that Ochsner Health System will be their preferred treatment provider.”

Dr Aimee Mackey concluded: “We are very pleased to have adopted this robust and accurate technology that will enable our department to effectively treat a greater number of patients. Magseed removes many of the complications associated with traditional wire and more fragile localization systems, and is easier to deploy and locate. This advanced, non-radioactive technology provides reassurance for clinicians and a more comfortable experience for patients.”

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

FDA Authorizes Software that Can Help Identify Prostate Cancer

The software is called Paige Prostate and is compatible for use with slide images that have been digitized using a scanner.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

By using this website you agree to accept Medical Device News Magazine Privacy Policy